← Leaderboards
Steven C. Schachter
Beth Israel Deaconess Medical Center
$10,007,385
Attributed
$10,007,385
Total exposure
18
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $14.4M · FY2008–25$20M$15M$10M$5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,185,973 · 20
By mechanism
U54$41,564,317 · 10
M01$1,166,873 · 8
N02$454,783 · 1
N01$0 · 1
Top collaborators
- Paolo Bonato19 shared
- John A Parrish3 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Michael Brandon Westover$15,983,729
- Margaret J Koziel$5,996,609
- Nira Pollock$9,552,528
- Roya Khosravi-Far$10,044,273
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationTechnologyProgramsAreaUnited States National Institutes Of HealthFundingNervous System DisorderDiagnosisResourcesPrototypeInterestEvaluationRadx TechInvestmentsNeurotechnologyCompanionsNeeds AssessmentCommunitiesCollaborationsSuccessOutreachAccelerationInfrastructurePerformance
Grant awards (70)
Center for Innovative NeuroTech Advancement - CINTA. 18058 Neurava$1,472,965
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA (20409 CoolSpine)$1,419,143
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA. 15999 Biomotum$1,201,485
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA (17041 Stanford)$1,200,000
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA (18716 CraniUS)$1,180,087
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA (20407 Hepius Lab)$1,149,277
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA. 15846 University of Arizona$1,133,544
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA (18408 Motif NeuroTech)$1,021,224
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA$1,000,000
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA. 15447 Neurastasis$773,617
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA (19819 Neurological Solutions, Inc)$683,070
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Resource Core$475,465
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Evaluation Core$406,253
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Administrative Core$387,052
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Outreach Core$233,429
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Evaluation Core$222,391
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Innovator Core$202,259
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Outreach Core$180,627
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Innovator Core$13,034
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Resource Core$13,034
U54 · FY2025 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA$2,940,899
U54 · FY2024 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA$1,329,031
U54 · FY2024 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA$1,225,748
U54 · FY2024 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA$1,208,978
U54 · FY2024 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Administrative Core$1,208,978
U54 · FY2024 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA$1,026,799
U54 · FY2024 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA$1,000,000
U54 · FY2024 · EB · contact PI
RADX INNOVATION FUNNEL FOR HIV DIAGNOSTICS - COORDINATION CENTER$454,783
N02 · FY2024 · HL · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Administrative Core$411,558
U54 · FY2024 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Evaluation Core$379,406
U54 · FY2024 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Outreach Core$209,036
U54 · FY2024 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA$5,637,312
U54 · FY2023 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Administrative Core$2,453,286
U54 · FY2023 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Evaluation Core$378,411
U54 · FY2023 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Outreach Core$211,510
U54 · FY2023 · EB · contact PI
Center for Innovative NeuroTech Advancement - CINTA$1,000,000
U54 · FY2022 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Administrative Core$413,307
U54 · FY2022 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Evaluation Core$383,256
U54 · FY2022 · EB · contact PI
Center for Innovative NeuroTech Advancement (CINTA) - Outreach Core$203,437
U54 · FY2022 · EB · contact PI
Point of Care Technology Research Center in Primary Care$1,881,231
U54 · FY2016 · EB
Point of Care Technology Research Center in Primary Care$1,852,256
U54 · FY2015 · EB
Point of Care Technology Research Center in Primary Care$1,841,922
U54 · FY2014 · EB
FEASIBILITY OF A COMBINED SEIZURE DETECTOR-VNS SYSTEM$3,377
M01 · FY2008 · RR · contact PI
TRIAL OF GP47779 (NHD OF OXCARBAZEPINE) ADMINISTERED IV TO INPATIENTS$0
M01 · FY2002 · RR
REMACEMIDE AS MONOTHERAPY IN PARTIAL ONSET SEIZURES$0
M01 · FY2002 · RR
EXTENSION TRIAL OF OXCARBAZEPINE IN PATIENTS W/ PARTIAL SEIZURES$0
M01 · FY2002 · RR
LOSIGAMONE AS MONOTHERAPY IN TREATMENT OF COMPLEX PARTIAL SEIZURES$0
M01 · FY2002 · RR
LOSIGAMONE AS MONOTHERAPY IN TREATMENT OF COMPLEX PARTIAL SEIZURES$0
M01 · FY2001 · RR
REMACEMIDE AS MONOTHERAPY IN PARTIAL ONSET SEIZURES$0
M01 · FY2001 · RR
EXTENSION TRIAL OF OXCARBAZEPINE IN PATIENTS W/ PARTIAL SEIZURES$0
M01 · FY2001 · RR
TRIAL OF GP47779 (NHD OF OXCARBAZEPINE) ADMINISTERED IV TO INPATIENTS$0
M01 · FY2001 · RR
EVALUATION OF ADD ON 534U87 TREATMENT OF PARTIAL SEIZURES$193,916
M01 · FY2000 · RR
PREGABALIN OPEN LABEL, FOLLOW ON SAFETY TRIAL IN PATIENTS W/ EPILEPSY$193,916
M01 · FY2000 · RR
PREGABALIN OPEN LABEL, FOLLOW ON SAFETY TRIAL IN PATIENTS W/ EPILEPSY$193,916
M01 · FY2000 · RR
PREGABALIN IN PATIENT MONOTHERAPY TRIAL IN PATIENTS W/ EPILEPSY$193,916
M01 · FY2000 · RR
PREGABALIN IN PATIENT MONOTHERAPY TRIAL IN PATIENTS W/ EPILEPSY$193,916
M01 · FY2000 · RR
EVALUATION OF ADD ON 534U87 TREATMENT OF PARTIAL SEIZURES$193,916
M01 · FY2000 · RR
EXTENSION TRIAL OF OXCARBAZEPINE IN PATIENTS W/ PARTIAL SEIZURES$0
M01 · FY2000 · RR
EXTENSION TRIAL OF OXCARBAZEPINE IN PATIENTS W/ PARTIAL SEIZURES$0
M01 · FY2000 · RR
TRIAL OF GP47779 (NHD OF OXCARBAZEPINE) ADMINISTERED IV TO INPATIENTS$0
M01 · FY2000 · RR
TRIAL OF GP47779 (NHD OF OXCARBAZEPINE) ADMINISTERED IV TO INPATIENTS$0
M01 · FY2000 · RR
TRIAL OF GP47779 (NHD OF OXCARBAZEPINE) ADMINISTERED IV TO INPATIENTS$0
M01 · FY2000 · RR
LOSIGAMONE AS MONOTHERAPY IN TREATMENT OF COMPLEX PARTIAL SEIZURES$0
M01 · FY2000 · RR
LOSIGAMONE AS MONOTHERAPY IN TREATMENT OF COMPLEX PARTIAL SEIZURES$0
M01 · FY2000 · RR
LOSIGAMONE AS MONOTHERAPY IN TREATMENT OF COMPLEX PARTIAL SEIZURES$0
M01 · FY2000 · RR
LOSIGAMONE IN TREATMENT OF COMPLEX CHILDRENS HOSPITAL$0
N01 · FY2000 · NS
REMACEMIDE AS MONOTHERAPY IN PARTIAL ONSET SEIZURES$0
M01 · FY2000 · RR
REMACEMIDE AS MONOTHERAPY IN PARTIAL ONSET SEIZURES$0
M01 · FY2000 · RR
REMACEMIDE AS MONOTHERAPY IN PARTIAL ONSET SEIZURES$0
M01 · FY2000 · RR
EXTENSION TRIAL OF OXCARBAZEPINE IN PATIENTS W/ PARTIAL SEIZURES$0
M01 · FY2000 · RR